GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » 6-1 Month Momentum %

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) 6-1 Month Momentum % : 7.96% (As of Jun. 25, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-06-25), Chongqing Genrix Biopharmaceutical Co's 6-1 Month Momentum % is 7.96%.

The industry rank for Chongqing Genrix Biopharmaceutical Co's 6-1 Month Momentum % or its related term are showing as below:

SHSE:688443's 6-1 Month Momentum % is ranked better than
68.59% of 1525 companies
in the Biotechnology industry
Industry Median: -8.22 vs SHSE:688443: 7.96

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's 6-1 Month Momentum %

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's 6-1 Month Momentum % falls into.



Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Chongqing Genrix Biopharmaceutical Co 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Headlines

No Headlines